HC Wainwright Forecasts InflaRx’s Q3 Earnings (NASDAQ:IFRX)

InflaRx N.V. (NASDAQ:IFRX) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller expects that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.51) EPS and FY2028 earnings at ($0.52) EPS.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of ($0.04) million during the quarter, compared to the consensus estimate of $0.03 million.

IFRX has been the topic of a number of other reports. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Leerink Partners restated a “market perform” rating and set a $2.00 price target (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Guggenheim lowered their price objective on shares of InflaRx from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.17.

InflaRx Price Performance

Shares of InflaRx stock opened at $0.94 on Monday. The business has a 50-day simple moving average of $0.93 and a 200 day simple moving average of $1.14. The firm has a market capitalization of $63.69 million, a price-to-earnings ratio of -1.24 and a beta of 1.48. InflaRx has a one year low of $0.71 and a one year high of $1.94.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Suvretta Capital Management LLC raised its stake in shares of InflaRx by 22.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after purchasing an additional 1,450,000 shares during the period. 683 Capital Management LLC grew its position in InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after buying an additional 1,065,000 shares during the period. Bank of America Corp DE bought a new position in InflaRx during the third quarter valued at about $3,316,000. Eversept Partners LP increased its holdings in InflaRx by 1.5% during the fourth quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after buying an additional 26,677 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in InflaRx in the first quarter worth about $766,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

Key Stories Impacting InflaRx

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: Company highlights promising Phase 2a izicopan data, progress toward Phase 2b readiness in hidradenitis suppurativa (HS), plans for PK bridging in China, active collaborator discussions, and a spring Capital Markets Day to outline the development path—these clinical and strategic updates are the main near‑term catalysts. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
• Positive Sentiment: Guggenheim maintained a Buy rating while lowering its price target from $22 to $14 — the cut reduces upside vs prior expectations but the firm still signals conviction in the story, which can support the stock. Guggenheim price target note (Benzinga)
• Positive Sentiment: HC Wainwright continues to carry a Buy rating with a $6 target and published near‑term EPS estimates (Q1 2026: -$0.14; Q2 2026: -$0.13), providing analyst support and a clear set of expectations for upcoming quarters. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: InflaRx reported Q4 EPS of ($0.17), which met consensus, reducing near‑term headline risk from the print itself. Press Release
• Neutral Sentiment: Market coverage and public filings (Business Insider / GlobeNewswire) provide a fuller corporate update on milestones and timelines; these items clarify strategy but do not immediately alter cash or clinical risk. InflaRx full‑year results (Business Insider)
• Negative Sentiment: Revenue remains negligible and the company reported revenue below estimates; InflaRx is still loss‑making with consensus full‑year EPS around -$1.04, underlining ongoing financing and execution risk. Zacks: Q4 loss, revenue miss
• Negative Sentiment: Cash, cash equivalents and marketable securities totaled €46.2M at 12/31/25, which the company says funds operations to mid‑2027 — this finite runway implies potential dilution or financing needs if clinical programs extend or expand. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.